{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:29:40Z","timestamp":1759336180247,"version":"3.28.0"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Over the past decade, atropine has emerged as an effective intervention for preventing myopia in children. Multiple randomized controlled trials, mainly from Asia, have demonstrated the safety and efficacy of topical atropine for myopia control. Both efficacy and side effects exhibit a positive dose-response relationship. This review focuses on new data from studies with predominantly white populations, ethnicity-dependent differences in efficacy and side effects, and primary prevention of incident myopia with atropine.<\/jats:p>","DOI":"10.1055\/a-2307-0363","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T23:45:35Z","timestamp":1716853535000},"page":"1134-1139","source":"Crossref","is-referenced-by-count":2,"title":["Topical Atropine for Myopia Control: A Review"],"prefix":"10.1055","volume":"241","author":[{"given":"Navid","family":"Farassat","sequence":"additional","affiliation":[{"name":"Medical Center, Eye Center, University Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaophthalmol.2016.4009","article-title":"Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With Myopia","volume":"134","author":"J WL Tideman","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ophtha.2021.04.032","article-title":"The Risks and Benefits of Myopia Control","volume":"128","author":"M A Bullimore","year":"2021","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.62.5.6","article-title":"IMI prevention of myopia and its progression","volume":"62","author":"J B Jonas","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"02","key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014758.pub2","article-title":"Interventions for myopia control in children: a living systematic review and network meta-analysis","author":"J G Lawrenson","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","first-page":"139","article-title":"On the Atropine Treatment of Acquired and Progressive Myopia","volume":"2","author":"H Derby","year":"1874","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5\u200a%, 0.1\u200a%, and 0.01\u200a% doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"A Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"W H Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report","volume":"129","author":"J C Yam","year":"2022","journal-title":"Ophthalmology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"100923","DOI":"10.1016\/j.preteyeres.2020.100923","article-title":"Efficacy in myopia control","volume":"83","author":"N A Brennan","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","article-title":"Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis","volume":"129","author":"A Ha","year":"2022","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","article-title":"Low\u2010concentration atropine eyedrops for myopia control in a multi\u2010racial cohort of Australian children: A randomised clinical trial","volume":"50","author":"S S Lee","year":"2022","journal-title":"Clin Experiment Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/aos.15761","article-title":"Myopia outcome study of atropine in children: Two-year result of daily 0.01\u200a% atropine in a European population","volume":"102","author":"J Loughman","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and Safety of 0.01\u200a% and 0.02\u200a% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial","volume":"141","author":"K Zadnik","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-Dose 0.01\u200a% Atropine Eye Drops vs. Placebo for Myopia Control","volume":"141","author":"M X Repka","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/ICL.0000000000000932","article-title":"Compounding of Low-Concentration Atropine for Myopia Control","volume":"48","author":"K Richdale","year":"2022","journal-title":"Eye Contact Lens"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/jpm14020175","article-title":"Two-Year Results of 0.01\u200a% Atropine Eye Drops and 0.1\u200a% Loading Dose for Myopia Progression Reduction in Danish Children: A Placebo-Controlled, Randomized Clinical Trial","volume":"14","author":"N C Hansen","year":"2024","journal-title":"J Pers Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e068822","DOI":"10.1136\/bmjopen-2022-068822","article-title":"Low-dose AtropIne for Myopia Control in Children (AIM): protocol for a randomised, controlled, double-blind, multicentre, clinical trial with two parallel arms","volume":"13","author":"N Farassat","year":"2023","journal-title":"BMJ Open"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1001\/jamaophthalmol.2023.5467","article-title":"Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study","volume":"142","author":"Y Li","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","article-title":"Biological Mechanisms of Atropine Control of Myopia","volume":"46","author":"A Upadhyay","year":"2020","journal-title":"Eye Contact Lens"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1167\/iovs.17-22562","article-title":"Myopia-Inhibiting Concentrations of Muscarinic Receptor Antagonists Block Activation of Alpha2A-Adrenoceptors In Vitro","volume":"59","author":"B J Carr","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1021\/pr500558y","article-title":"Involvement of GABA transporters in atropine-treated myopic retina as revealed by iTRAQ quantitative proteomics","volume":"13","author":"V A Barathi","year":"2014","journal-title":"J Proteome Res"},{"key":"ref23","first-page":"1277","article-title":"Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation","volume":"15","author":"V A Barathi","year":"2009","journal-title":"Mol Vis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1017\/s0952523800171184","article-title":"Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick","volume":"17","author":"H N Schwahn","year":"2000","journal-title":"Vis Neurosci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"8528315","DOI":"10.1155\/2018\/8528315","article-title":"Effect of Atropine Eye Drops on Choroidal Thinning Induced by Hyperopic Retinal Defocus","volume":"2018","author":"S T Chiang","year":"2018","journal-title":"J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1475-1313.2012.00940.x","article-title":"Scleral changes induced by atropine in chicks as an experimental model of myopia","volume":"32","author":"P Gallego","year":"2012","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","article-title":"Side effects of topical atropine 0.05\u200a% compared to 0.01\u200a% for myopia control in German school children: a pilot study","volume":"41","author":"L Joachimsen","year":"2021","journal-title":"Int Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/OPX.0000000000000037","article-title":"Maximum atropine dose without clinical signs or symptoms","volume":"90","author":"J Cooper","year":"2013","journal-title":"Optom Vis Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/OPX.0000000000001884","article-title":"Effect of Combining 0.01\u200a% Atropine with Soft Multifocal Contact Lenses on Myopia Progression in Children","volume":"99","author":"J H Jones","year":"2022","journal-title":"Optom Vis Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1016\/j.jfma.2022.05.005","article-title":"Efficacy of atropine, orthokeratology, and combined atropine with orthokeratology for childhood myopia: A systematic review and network meta-analysis","volume":"121","author":"H R Tsai","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"101723","DOI":"10.1016\/j.clae.2022.101723","article-title":"Combined 0.01\u200a% atropine with orthokeratology in childhood myopia control (AOK) study: A 2-year randomized clinical trial","volume":"46","author":"Q Tan","year":"2023","journal-title":"Cont Lens Anterior Eye"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e0281816","DOI":"10.1371\/journal.pone.0281816","article-title":"A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS\/atropine","volume":"18","author":"P Nucci","year":"2023","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"22311","DOI":"10.1038\/s41598-022-25599-z","article-title":"Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia","volume":"12","author":"Z Huang","year":"2022","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/iovs.64.6.3","article-title":"IMI-Management and Investigation of High Myopia in Infants and Young Children","volume":"64","author":"I Flitcroft","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/opo.13115","article-title":"Myopia control in Mendelian forms of myopia","volume":"43","author":"E van der Sande","year":"2023","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/aos.13603","article-title":"Axial length growth and the risk of developing myopia in European children","volume":"96","author":"J WL Tideman","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/opo.13058","article-title":"Myopia: An ounce of prevention is worth a pound of cure","volume":"43","author":"M A Bullimore","year":"2023","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.24162","article-title":"Effect of Low-Concentration Atropine Eyedrops vs. Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial","volume":"329","author":"J C Yam","year":"2023","journal-title":"JAMA"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2307-0363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:42:28Z","timestamp":1730803348000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2307-0363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,9]]},"published-print":{"date-parts":[[2024,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2307-0363","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"type":"print","value":"0023-2165"},{"type":"electronic","value":"1439-3999"}],"subject":[],"published":{"date-parts":[[2024,5,27]]}}}